MLYS

SEC source: 0001933414-24-000018 · wk-form4_1716495632.xml · derivative · entry 1

Litzka Olivier · CIK 0001963940 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2034-05-22

F1 · derivative.exercise_date: The stock option award vests in 12 substantially equal monthly installments beginning on June 22, 2024. In the event that the next annual meeting of stockholders occurs prior to May 22, 2025, any remaining unvested portion of the stock option award will vest on the date of such meeting.

SEC source: 0001415889-24-014734 · form4-05282024_100522.xml · derivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director

RA Capital Healthcare Fund LP · CIK 0001315082 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director

Shah Rajeev M. · CIK 0001619841 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2034-05-22

F1 · derivative.exercise_date: The stock option award vests in 12 substantially equal monthly installments beginning on June 22, 2024. In the event that the next annual meeting of stockholders occurs prior to May 22, 2025, any remaining unvested portion of the stock option award will vest on the date of such meeting.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

F3 · ownership.nature: Derek DiRocco is a Partner of the Adviser who serves on the Issuer's board of directors. Under Dr. DiRocco's arrangement with the Adviser, Dr. DiRocco holds the option for the benefit of the Fund and the Nexus Fund III. Dr. DiRocco is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund III to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.

SEC source: 0001933414-25-000001 · wk-form4_1736290727.xml · derivative · entry 2

Slingsby Brian Taylor · CIK 0001963901 · Director · 10% owner

Catalys Pacific Fund, LP · CIK 0001746274 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2034-05-22

F1 · kind: Represents stock options transferred pursuant to an option transfer agreement between the Reporting Person and Catalys Pacific Fund, LP.

F2 · derivative.exercise_date: The stock option award vests in 12 substantially equal monthly installments beginning on June 22, 2024. In the event that the next annual meeting of stockholders occurs prior to May 22, 2025, any remaining unvested portion of the stock option award will vest on the date of such meeting.

F3 · ownership.nature: Represents securities held directly by Catalys Pacific Fund, LP. The general partner of Catalys Pacific Fund, LP is Catalys Pacific Fund GP, LP. Brian Taylor Slingsby is the managing partner of Catalys Pacific, LLC, which is the general partner of Catalys Pacific Fund GP, LP. Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby may be deemed to have voting and investment power over the shares held of record by Catalys Pacific Fund, LP. Each of Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

SEC source: 0001933414-25-000001 · wk-form4_1736290727.xml · derivative · entry 1

Slingsby Brian Taylor · CIK 0001963901 · Director · 10% owner

Catalys Pacific Fund, LP · CIK 0001746274 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 22,000 shares

Expires 2034-05-22

F1 · kind: Represents stock options transferred pursuant to an option transfer agreement between the Reporting Person and Catalys Pacific Fund, LP.

F2 · derivative.exercise_date: The stock option award vests in 12 substantially equal monthly installments beginning on June 22, 2024. In the event that the next annual meeting of stockholders occurs prior to May 22, 2025, any remaining unvested portion of the stock option award will vest on the date of such meeting.

SEC source: 0001628280-24-023621 · wk-form4_1715805784.xml · derivative · entry 4

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 196,706

Underlying: Common Stock · 6,348 shares

Expires 2032-07-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $1.07 per share on the Reporting Person's Form 3 filed on February 9, 2023.

F4 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2023, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001628280-24-023621 · wk-form4_1715805784.xml · derivative · entry 3

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,138

Underlying: Common Stock · 5,018 shares

Expires 2031-03-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023.

F2 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001628280-24-023621 · wk-form4_1715805784.xml · nonDerivative · entry 2

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,363

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001628280-24-023621 · wk-form4_1715805784.xml · nonDerivative · entry 1

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,015

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001628280-24-022631 · wk-form4_1715372242.xml · derivative · entry 3

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 203,054

Underlying: Common Stock · 100 shares

Expires 2031-07-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $1.07 per share on the Reporting Person's Form 3 filed on February 9, 2023.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2023.

F3 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2023, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001628280-24-022631 · wk-form4_1715372242.xml · nonDerivative · entry 2

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 66,997

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2023.

SEC source: 0001628280-24-022631 · wk-form4_1715372242.xml · nonDerivative · entry 1

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 67,097

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2023.

SEC source: 0001933414-24-000013 · wk-form4_1713212679.xml · derivative · entry 4

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 203,154

Underlying: Common Stock · 6,349 shares

Expires 2031-07-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $1.07 per share on the Reporting Person's Form 3 filed on February 9, 2023.

F4 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2023, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-24-000013 · wk-form4_1713212679.xml · nonDerivative · entry 2

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,997

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001933414-24-000013 · wk-form4_1713212679.xml · derivative · entry 3

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,156

Underlying: Common Stock · 5,017 shares

Expires 2031-03-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023.

F2 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-24-000013 · wk-form4_1713212679.xml · nonDerivative · entry 1

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,648

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001628280-24-011003 · wk-form4_1710365726.xml · derivative · entry 4

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 209,503

Underlying: Common Stock · 6,348 shares

Expires 2031-07-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $1.07 per share on the Reporting Person's Form 3 filed on February 9, 2023.

F4 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2023, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001628280-24-011003 · wk-form4_1710365726.xml · nonDerivative · entry 2

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,631

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001628280-24-011003 · wk-form4_1710365726.xml · derivative · entry 3

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,173

Underlying: Common Stock · 5,017 shares

Expires 2031-03-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023.

F2 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001628280-24-011003 · wk-form4_1710365726.xml · nonDerivative · entry 1

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,283

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001628280-24-005065 · wk-form4_1708032366.xml · derivative · entry 1

Levy Adam Scott · CIK 0001693134 · CFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2034-02-13

F1 · derivative.exercise_date: The stock option vests as to 25% of the total number of shares of Common Stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of Common Stock subject to the option on each monthly anniversary thereafter.

SEC source: 0001628280-24-005066 · wk-form4_1708032387.xml · derivative · entry 1

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2034-02-13

F1 · derivative.exercise_date: The stock option vests as to 25% of the total number of shares of Common Stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of Common Stock subject to the option on each monthly anniversary thereafter.

SEC source: 0001628280-24-005064 · wk-form4_1708032345.xml · derivative · entry 1

Congleton Jon · CIK 0001644975 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 425,000

Underlying: Common Stock · 425,000 shares

Expires 2034-02-13

F1 · derivative.exercise_date: The stock option vests as to 25% of the total number of shares of Common Stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of Common Stock subject to the option on each monthly anniversary thereafter.

SEC source: 0001933414-24-000007 · wk-form4_1707858518.xml · derivative · entry 4

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 215,851

Underlying: Common Stock · 6,349 shares

Expires 2031-07-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $1.07 per share on the Reporting Person's Form 3 filed on February 9, 2023.

F4 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2023, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-24-000007 · wk-form4_1707858518.xml · derivative · entry 3

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,190

Underlying: Common Stock · 5,017 shares

Expires 2031-03-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023.

F2 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-24-000007 · wk-form4_1707858518.xml · nonDerivative · entry 2

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,266

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001933414-24-000007 · wk-form4_1707858518.xml · nonDerivative · entry 1

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,917

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-003861 · form4-02152024_020204.xml · nonDerivative · entry 1

AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 5,074,916

F1 · ownership.nature: Represents securities held directly by Samsara BioCapital, L.P. ("Samsara LP"). Dr. Akkaraju has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his pecuniary interest therein.

SEC source: 0001415889-24-003853 · form4-02152024_120216.xml · derivative · entry 3

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director

RA Capital Healthcare Fund LP · CIK 0001315082 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director

Shah Rajeev M. · CIK 0001619841 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 549,755

Underlying: Common Stock · 549,755 shares

Expires not disclosed

F4 · derivative.exercise_date: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. The Fund may not exercise the Pre-Funded Warrants to the extent that, following exercise, the Fund, together with its affiliates and other attribution parties, would own more than 9.99% of the Common Stock outstanding.

F4 · derivative.expiration_date: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. The Fund may not exercise the Pre-Funded Warrants to the extent that, following exercise, the Fund, together with its affiliates and other attribution parties, would own more than 9.99% of the Common Stock outstanding.

F1 · ownership.nature: These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001415889-24-003853 · form4-02152024_120216.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director

RA Capital Healthcare Fund LP · CIK 0001315082 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director

Shah Rajeev M. · CIK 0001619841 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 2,983,755

F1 · ownership.nature: These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001415889-24-003859 · form4-02152024_020259.xml · nonDerivative · entry 1

Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner

Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 5,074,916

F1 · ownership.nature: Represents securities held directly by Samsara BioCapital, L.P. Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara BioCapital, L.P. ("Samsara LP") and may be deemed to beneficially own the shares held by Samsara LP. Samsara LLC disclaims beneficial ownership in these shares except to the extent of its pecuniary interest therein.

SEC source: 0001933414-24-000003 · wk-form4_1705093286.xml · derivative · entry 4

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 222,200

Underlying: Common Stock · 6,348 shares

Expires 2031-07-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $1.07 per share on the Reporting Person's Form 3 filed on February 9, 2023.

F5 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-24-000003 · wk-form4_1705093286.xml · nonDerivative · entry 2

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,900

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001933414-24-000003 · wk-form4_1705093286.xml · derivative · entry 3

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,207

Underlying: Common Stock · 5,017 shares

Expires 2031-03-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023.

F3 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-24-000003 · wk-form4_1705093286.xml · nonDerivative · entry 1

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,552

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: This balance includes 1,466 shares purchased under the Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan that were not previously reported.

SEC source: 0001933414-23-000094 · wk-form4_1702418911.xml · derivative · entry 2

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,224

Underlying: Common Stock · 5,018 shares

Expires 2031-03-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023.

F2 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-23-000094 · wk-form4_1702418911.xml · nonDerivative · entry 1

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,069

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001933414-23-000093 · wk-form4_1701118862.xml · nonDerivative · entry 1

Congleton Jon · CIK 0001644975 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,049,068

F1 · price: The price reported is the weighted-average purchase price, purchased in multiple transactions at prices ranging from $5.8850 to $5.9996. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.

SEC source: 0001933414-23-000091 · wk-form4_1700003914.xml · derivative · entry 2

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,242

Underlying: Common Stock · 5,017 shares

Expires 2031-03-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023.

F2 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-23-000091 · wk-form4_1700003914.xml · nonDerivative · entry 1

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,051

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001933414-23-000088 · wk-form4_1699395330.xml · derivative · entry 2

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,259

Underlying: Common Stock · 10,034 shares

Expires 2031-03-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023.

F2 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-23-000088 · wk-form4_1699395330.xml · nonDerivative · entry 1

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,034

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001933414-23-000079 · wf-form4_169472241630395.xml · derivative · entry 1

Karydas Daphne · CIK 0001816952 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,000

Underlying: Common Stock · 44,000 shares

Expires 2033-09-13

F1 · derivative.exercise_date: The stock option vests in 36 monthly installments beginning on October 13, 2023.

SEC source: 0001933414-23-000078 · wf-form4_169472239867794.xml · derivative · entry 1

SBLENDORIO GLENN · CIK 0001277478 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,000

Underlying: Common Stock · 44,000 shares

Expires 2033-09-13

F1 · derivative.exercise_date: The stock option vests in 36 monthly installments beginning on October 13, 2023.

SEC source: 0001933414-23-000067 · wf-form4_169417735412478.xml · nonDerivative · entry 1

Congleton Jon · CIK 0001644975 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,044,818

F1 · price: The price reported is the weighted-average purchase price, purchased in multiple transactions at prices ranging from $11.9860 to $12.1202. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.

SEC source: 0001933414-23-000065 · wf-form4_169264818560082.xml · nonDerivative · entry 1

Congleton Jon · CIK 0001644975 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,042,568

F1 · price: The price reported is the weighted-average purchase price, purchased in multiple transactions at prices ranging from $12.02 to $12.1473. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.

SEC source: 0001933414-23-000062 · wf-form4_169179547763057.xml · derivative · entry 9

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 228,548

Underlying: Common Stock · 76,182 shares

Expires 2031-07-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $1.07 per share on the Reporting Person's Form 3 filed on February 9, 2023.

F6 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-23-000062 · wf-form4_169179547763057.xml · derivative · entry 8

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,293

Underlying: Common Stock · 80,909 shares

Expires 2031-03-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023.

F4 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-23-000062 · wf-form4_169179547763057.xml · nonDerivative · entry 6

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F2 · price: The price reported is the weighted-average sales price, sold in multiple transactions at prices ranging from $12.39 to $13.185, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001933414-23-000062 · wf-form4_169179547763057.xml · nonDerivative · entry 5

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,182

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001933414-23-000062 · wf-form4_169179547763057.xml · nonDerivative · entry 4

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F2 · price: The price reported is the weighted-average sales price, sold in multiple transactions at prices ranging from $12.39 to $13.185, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4.